Invex Therapeutics (ASX:IXC) EV-to-EBITDA : -0.66 (As of Jun. 26, 2025)

Invex Therapeutics EV-to-EBITDA Chart

Invex Therapeutics Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
EV-to-EBITDA	Get a 7-Day Free Trial						-	0.83	-	0.45	-

Competitive Comparison of Invex Therapeutics's EV-to-EBITDA

For the Biotechnology subindustry, Invex Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Invex Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Invex Therapeutics's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Invex Therapeutics's EV-to-EBITDA falls into.

Invex Therapeutics EV-to-EBITDA Calculation

Invex Therapeutics's EV-to-EBITDA for today is calculated as:

Invex Therapeutics's current Enterprise Value is A$0.88 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Invex Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was A$-1.33 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Invex Therapeutics  (ASX:IXC) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Invex Therapeutics's PE Ratio (TTM) for today is calculated as:

Invex Therapeutics's share price for today is A$0.089.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Invex Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was A$0.001.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?

Invex Therapeutics EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Invex Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Invex Therapeutics Business Description